ST Pharm Signs 10.8 Billion KRW Oligonucleotide Therapeutics Supply Contract with European Global Pharmaceutical Company
[Asia Economy Reporter Park Jun-yi] ST Pharm announced on the 8th that it has signed a supply contract worth $9,904,910 (approximately 10.81616 billion KRW) for clinical phase 3 chronic disease oligonucleotide therapeutic raw materials (oligonucleotides) with a Europe-based global pharmaceutical company.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- Suspicious Starbucks Numbers?... 'Tank Day' Controversy Spreads from May 18 to Sewol Ferry and Park Geun-hye
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The contract amount represents 11.6% of the consolidated sales as of 2019. The contract will end on June 30, 2022.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
